Literature DB >> 15288443

Amyloid beta-protein induced electrophysiological changes are dependent on aggregation state: N-methyl-D-aspartate (NMDA) versus non-NMDA receptor/channel activation.

Chianping Ye1, Dominic M Walsh, Dennis J Selkoe, Dean M Hartley.   

Abstract

Alzheimer's disease (AD) is a progressive neurodegenerative disease, however, the underlying mechanism driving this condition is unknown. Unexplored is the possibility that the time-dependent generation of different Abeta assemblies may underlie the pathogenic cascade with biophysically distinct structures interacting with unique biological targets. Thus, the presence of subtle alterations in synaptic function during the earliest clinical phase of AD may be mediated by diffusible assemblies of the amyloid beta-protein (Abeta). Using primary neocortical cultures, here we compare the synaptic responses induced by two different Abeta assemblies, protofibrils (PFs) and fibrils (FBs), and demonstrate for the first time that neuronal activation was selectively dependent on the assembly state of Abeta. PF-induced activity was specifically attenuated by the N-methyl-D-aspartate (NMDA) receptor antagonist, D-APV. In contrast, the non-NMDA glutamate receptor antagonist, NBQX, preferentially reduced FB-induced activity. In support, removal of Mg(2+) from the medium, which enhances NMDA channels, increased both PF- or FB-induced activation, but D-APV was more effective in attenuating PF-induced excitatory activity. These findings suggest that PFs may activate neurons differently than fibrils and lend support to the hypothesis that pre-fibrillar assemblies of Abeta may play an important role in the development of AD-type synaptic deficits.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15288443     DOI: 10.1016/j.neulet.2004.05.060

Source DB:  PubMed          Journal:  Neurosci Lett        ISSN: 0304-3940            Impact factor:   3.046


  26 in total

1.  Preparation and characterization of toxic Abeta aggregates for structural and functional studies in Alzheimer's disease research.

Authors:  Asad Jan; Dean M Hartley; Hilal A Lashuel
Journal:  Nat Protoc       Date:  2010-06-03       Impact factor: 13.491

Review 2.  Alzheimer's disease, β-amyloid, glutamate, NMDA receptors and memantine--searching for the connections.

Authors:  Wojciech Danysz; Chris G Parsons
Journal:  Br J Pharmacol       Date:  2012-09       Impact factor: 8.739

3.  Certain inhibitors of synthetic amyloid beta-peptide (Abeta) fibrillogenesis block oligomerization of natural Abeta and thereby rescue long-term potentiation.

Authors:  Dominic M Walsh; Matthew Townsend; Marcia B Podlisny; Ganesh M Shankar; Julia V Fadeeva; Omar El Agnaf; Dean M Hartley; Dennis J Selkoe
Journal:  J Neurosci       Date:  2005-03-09       Impact factor: 6.167

Review 4.  The development of anti-amyloid therapy for Alzheimer's disease : from secretase modulators to polymerisation inhibitors.

Authors:  Paul S Aisen
Journal:  CNS Drugs       Date:  2005       Impact factor: 5.749

5.  Distinctive roles of different beta-amyloid 42 aggregates in modulation of synaptic functions.

Authors:  Hsueh-Cheng Chiang; Koichi Iijima; Inessa Hakker; Yi Zhong
Journal:  FASEB J       Date:  2009-03-02       Impact factor: 5.191

Review 6.  Structure-function relationships of pre-fibrillar protein assemblies in Alzheimer's disease and related disorders.

Authors:  F Rahimi; A Shanmugam; G Bitan
Journal:  Curr Alzheimer Res       Date:  2008-06       Impact factor: 3.498

Review 7.  Alzheimer's disease amyloid beta-protein and synaptic function.

Authors:  Tomas Ondrejcak; Igor Klyubin; Neng-Wei Hu; Andrew E Barry; William K Cullen; Michael J Rowan
Journal:  Neuromolecular Med       Date:  2009-09-16       Impact factor: 3.843

8.  Beta-amyloid causes depletion of synaptic vesicles leading to neurotransmission failure.

Authors:  Jorge Parodi; Fernando J Sepúlveda; Jorge Roa; Carlos Opazo; Nibaldo C Inestrosa; Luis G Aguayo
Journal:  J Biol Chem       Date:  2009-11-13       Impact factor: 5.157

Review 9.  Role of Glutamate and NMDA Receptors in Alzheimer's Disease.

Authors:  Rui Wang; P Hemachandra Reddy
Journal:  J Alzheimers Dis       Date:  2017       Impact factor: 4.472

Review 10.  The dysregulation of intracellular calcium in Alzheimer disease.

Authors:  Charlene Supnet; Ilya Bezprozvanny
Journal:  Cell Calcium       Date:  2010-01-18       Impact factor: 6.817

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.